抗PAD4抗体将PAD4自身免疫与CTL相关类风湿关节炎联系起来
该研究以T-LGLL/RA为CTL相关RA模型,比较RA、T-LGLL/RA、T-LGLL及健康对照的血清学、遗传学和免疫学特征。T-LGLL/RA患者抗PAD4抗体频率显著高于RA(60% vs 27%,P < .0001),且PADI4 SNP与抗PAD4阳性RA相关,活化STAT3突变与抗PAD4抗体相关,抗PAD4阳性RA富集CD57+、CD7低表达TEMRA CTL,并可检测到PAD4特异性CTL。结论提示PAD4自身免疫与CTL相关疾病之间存在机制联系。
要点
- T-LGLL/RA患者抗PAD4抗体频率为60%,显著高于RA患者的27%(P < .0001)。
- 抗PAD4阳性RA富集CD57+、CD7低表达TEMRA CTL,并存在PAD4特异性CTL。
- 活化STAT3突变与T-LGLL/RA及RA中的抗PAD4抗体相关。
核心结论
- 研究数据表明PAD4自身免疫与RA中CTL相关疾病之间存在机制联系。
研究设计与样本
- 研究使用RA、T-LGLL/RA、T-LGLL患者及健康对照的血样和配对临床数据。
- 血清学采用抗CCP3.1 ELISA、多重RA自身抗原阵列及放射性标记PAD3和PAD4免疫沉淀。
- 遗传学采用PADI4 SNP TaqMan基因分型及ddPCR检测STAT3突变,并用流式细胞术和五聚体结合试验分析CTL。
主要发现
- T-LGLL/RA患者较RA患者抗瓜氨酸化蛋白抗体反应增强,抗PAD4抗体频率为60% vs 27%(P < .0001)。
- T-LGLL患者中PADI4 SNP与抗PAD4阳性RA相关(20% vs 3%,P = .02)。
- 抗PAD4抗体水平与中性粒细胞绝对计数呈负相关(Spearman's rho = -0.236;P = .02)。
- 活化STAT3突变与抗PAD4抗体在T-LGLL/RA(90% vs 74%,P = .047)和RA(39% vs 9%,P = .002)中相关。
- 抗PAD4阳性RA富集CD57+、CD7低表达TEMRA CTL,PAD4特异性CTL表达CD69、CD57、KLRG1及TEMRA表型。
临床怎么用
- 在RA中检测抗PAD4抗体可能有助于识别CTL相关疾病表型。
- 对抗PAD4阳性RA患者可关注CD57+、CD7低表达TEMRA CTL及STAT3突变状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to study the serologic, genetic, and immunologic underpinnings associated with cytotoxic T lymphocytes (CTLs) in rheumatoid arthritis (RA), using T-large granular lymphocytic leukaemia with comorbid RA (T-LGLL/RA) as a model of CTL-linked RA. METHODS: We used blood samples and paired clinical data from patients with RA, T-LGLL/RA, T-LGLL and healthy controls. Serological characterisation was performed using anti-cyclic citrullinated peptide 3.1 (anti-CCP3.1) enzyme-linked immunosorbent assay, multiplex RA autoantigen array, and radiolabelled peptidylarginine deiminase type III and IV (PAD4) immunoprecipitations. Genetic characterisation was performed using PADI4 single nucleotide polymorphism TaqMan genotyping assays and droplet digital polymerase chain reaction for signal transducer and activator of transcription 3 (STAT3) mutations. Multiparameter flow cytometry and pentamer binding assays were performed to immunophenotype CTLs and characterise PAD4-specific CTLs, respectively. RESULTS: Patients with T-LGLL/RA had enhanced anticitrullinated protein antibody responses compared with RA, and a strikingly higher frequency of anti-PAD4 antibodies (60% vs 27%, P < .0001). Among patients with T-LGLL, PADI4 single nucleotide polymorphisms were associated with anti-PAD4-positive RA (20% vs 3%, P = .02), and anti-PAD4 antibody levels were inversely correlated with absolute neutrophil count (Spearman's rho = -0.236; P = .02). Activating STAT3 mutations were associated with anti-PAD4 antibodies in both T-LGLL/RA (90% vs 74%, P = .047) and RA (39% vs 9%, P = .002). Flow cytometric characterisation of CTLs showed that anti-PAD4-positive RA was enriched for CD57+, CD7 low, T effector memory cells re-expressing CD45RA (TEMRA) CTLs. Furthermore, PAD4-specific CTLs were detected in anti-PAD4+ patients with RA and expressed elevated levels of CD69, CD57, and KLRG1, and a TEMRA phenotype. CONCLUSIONS: These data demonstrate a mechanistic link between autoimmunity to PAD4 and CTL-associated disease in RA.
引用
- Ananth K, Moosic KB, Gomez-Banuelos E, et al. Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis. Ann Rheum Dis. 2026. PMID: 42120292. doi:10.1016/j.ard.2026.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。